- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 01.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB - Business Update first quarter 2026 | 1 | Cision News | ||
| 01.04. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the sixth exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 3 | Cision News | ||
| 06.03. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB publishes Business Update ahead of next value creation phase | 1 | Cision News | ||
| 20.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works publishes Year-end report Q4 2025 | 5 | Cision News | ||
| 17.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order from Returning Customer | 1 | Cision News | ||
| 19.01. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 5 of 11 | 5 | Cision News | ||
| 02.01. | BIO-WORKS TECHNOLOGIES AB: Business Update | 1 | Cision News | ||
| 29.12.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Two WorkBeads 100S and 100Q Orders Worth SEK 4 Million | 5 | Cision News | ||
| 15.12.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB Annual General Meeting to be held on Thursday 4 of June 2026 | 2 | Cision News | ||
| 07.11.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports third quarter 2025 | 1 | Cision News | ||
| 06.11.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads 40S from contract manufacturer in Europe | 3 | Cision News | ||
| 29.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works forms strategic partnership with Zenmindes Biotechnology to strengthen presence in China | 1 | Cision News | ||
| 21.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works two largest shareholders, members of the board and the CEO have all exercised all their Warrants TO2 | 1 | Cision News | ||
| 17.10.25 | BIO-WORKS TECHNOLOGIES AB: Correction: Bio-Works receives order for WorkBeads affimAb valued at approximately SEK 8.3 million | 4 | Cision News | ||
| 17.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads affimAb valued at approximately SEK 8.3 million | 1 | Cision News | ||
| 16.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 4 of 11 | 1 | Cision News |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HELIX BIOPHARMA | 1,240 | +38,55 % | Helix Biopharma GAAP EPS of -$0.05 | ||
| DAMORA THERAPEUTICS | 24,360 | 0,00 % | Damora Therapeutics, Inc.: Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors | -- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter... ► Artikel lesen | |
| QIAGEN | 34,290 | -2,89 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| EVOTEC | 4,470 | -0,73 % | Evotec vor Kurssprung? Analysten und Charttechnik signalisieren Aufwärtspotenzial! | ||
| CG ONCOLOGY | 69,85 | 0,00 % | H.C. Wainwright hebt Kursziel für CG Oncology auf 100 US-Dollar an | ||
| ARCELLX | 114,80 | +0,05 % | Gilead extends Arcellx tender offer deadline to April 24 | ||
| BIONTECH | 77,20 | -2,40 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| ERASCA | 17,060 | 0,00 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 43,190 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| NUVALENT | 102,35 | -1,38 % | Nuvalent, Inc.: Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC | New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trial
CAMBRIDGE, Mass., April 7, 2026 /PRNewswire/... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 54,82 | 0,00 % | What's Going On With Structure Therapeutics Stock On Wednesday? | ||
| MINERALYS THERAPEUTICS | 28,300 | +0,18 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer | RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,610 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| TYRA BIOSCIENCES | 37,680 | -3,14 % | Tyra Biosciences, Inc. - 8-K, Current Report | ||
| RELAY THERAPEUTICS | 13,490 | 0,00 % | Healthcare quant check: RLAY and TNGX lead Seeking Alpha's top picks ahead of Q1 earnings |
BIO-WORKS TECHNOLOGIES AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,311 Euro und damit +1,30 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIO-WORKS TECHNOLOGIES AB finden Sie auf Wallstreet Online.